Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics

Journal of the American College of Cardiology

Volumn 73, Issue 15, 2019, Pages 1931-1944

  Santos Gallego, Carlos G ^a   Requena Ibanez, Juan Antonio ^a,b   San Antonio, Rodolfo ^a,c   Ishikawa, Kiyotake ^a   Watanabe, Shin ^a   Picatoste, Belen ^d   Flores, Eduardo ^a,c   Garcia Ropero, Alvaro ^a   Sanz, Javier ^a   Hajjar, Roger J ^a   Fuster, Valentin ^a   Badimon, Juan J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Hospital of Ciudad Real   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

animal models; cardiac remodeling; diabetes; heart failure; myocardial metabolism; SGLT2 inhibition

Indexed keywords

BRANCHED CHAIN AMINO ACID; EMPAGLIFLOZIN; FATTY ACID; PLACEBO; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; CORONARY ARTERY; CORONARY SINUS; ENERGY YIELD; FEMALE; GLUCOSE INTAKE; GLUCOSE TRANSPORT; HEART FAILURE; HEART LEFT VENTRICLE; HEART MUSCLE METABOLISM; HEART VENTRICLE REMODELING; HORMONAL REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; THREE DIMENSIONAL ECHOCARDIOGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALYSIS OF VARIANCE; ANIMAL; DIABETES MELLITUS; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG EFFECT; HEART FUNCTION TEST; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; NONPARAMETRIC TEST; PHARMACOLOGY; PHYSIOLOGY; PIG; PROCEDURES; RANDOMIZATION; REFERENCE VALUE;

ANALYSIS OF VARIANCE; ANIMALS; BENZHYDRYL COMPOUNDS; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY, THREE-DIMENSIONAL; GLUCOSIDES; HEART FAILURE; HEART FUNCTION TESTS; RANDOM ALLOCATION; REFERENCE VALUES; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; STATISTICS, NONPARAMETRIC; STROKE VOLUME; SWINE; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 85063956691     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2019.01.056     Document Type: Article

References (39)

1. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
2. Emdin, C.A., Rahimi, K., Neal, B., Callender, T., Perkovic, V., Patel, A., Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 313 (2015), 603–615.
3. Wende, A.R., Brahma, M.K., McGinnis, G.R., Young, M.E., Metabolic origins of heart failure. J Am Coll Cardiol Basic Transl Sci 2 (2017), 297–310.
4. Ferrannini, E., Mark, M., Mayoux, E., CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39 (2016), 1108–1114.
5. Mudaliar, S., Alloju, S., Henry, R.R., Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME Study? A unifying hypothesis. Diabetes Care 39 (2016), 1115–1122.
6. Ferrannini, E., Muscelli, E., Frascerra, S., et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124 (2014), 499–508.
7. Ferrannini, E., Baldi, S., Frascerra, S., et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65 (2016), 1190–1195.
8. Santos-Gallego, C.G., Vahl, T.P., Goliasch, G., et al. Sphingosine-1-phosphate receptor agonist fingolimod increases myocardial salvage and decreases adverse postinfarction left ventricular remodeling in a porcine model of ischemia/reperfusion. Circulation 133 (2016), 954–966.
9. Sun, H., Olson, K.C., Gao, C., et al. Catabolic defect of branched-chain amino acids promotes heart failure. Circulation 133 (2016), 2038–2049.
10. Bedi, K.C. Jr., Snyder, N.W., Brandimarto, J., et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation 133 (2016), 706–716.
11. Flores, E., Santos-Gallego, C.G., Diaz-Mejia, N., Badimon, J.J., Do the SGLT-2 inhibitors offer more than hypoglycemic activity?. Cardiovasc Drugs Ther 32 (2018), 213–222.
12. Marx, N., McGuire, D.K., Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J 37 (2016), 3192–3200.
13. Baartscheer, A., Schumacher, C.A., Wust, R.C., et al. Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits. Diabetologia 60 (2017), 568–573.
14. Theroux, P., Chaitman, B.R., Danchin, N., et al., for the Guard during ischemia against necrosis (GUARDIAN) Investigators. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Circulation 102 (2000), 3032–3038.
15. Konstam, M.A., Kramer, D.G., Patel, A.R., Maron, M.S., Udelson, J.E., Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. J Am Coll Cardiol Img 4 (2011), 98–108.
16. Cohn, J.N., Ferrari, R., Sharpe, N., on behalf of an International Forum on Cardiac Remodeling. Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 35 (2000), 569–582.
17. White, H.D., Norris, R.M., Brown, M.A., Brandt, P.W., Whitlock, R.M., Wild, C.J., Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76 (1987), 44–51.
18. Migrino, R.Q., Young, J.B., Ellis, S.G., et al., for the GUSTO-I Angiographic Investigators. End-systolic volume index is a strong predictor of early and late mortality. Circulation 96 (1997), 116–121.
19. Verma, A., Meris, A., Skali, H., et al. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. J Am Coll Cardiol Img 1 (2008), 582–591.
20. Mannaerts, H.F., van der Heide, J.A., Kamp, O., Stoel, M.G., Twisk, J., Visser, C.A., Early identification of left ventricular remodelling after myocardial infarction, assessed by transthoracic 3D echocardiography. Eur Heart J 25 (2004), 680–687.
21. Benedict, C.R., Shelton, B., Johnstone, D.E., et al., for the SOLVD Investigators. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation 94 (1996), 690–697.
22. Kragelund, C., Gronning, B., Kober, L., Hildebrandt, P., Steffensen, R., N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 352 (2005), 666–675.
23. Kimura, I., Inoue, D., Maeda, T., et al. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc Natl Acad Sci U S A 108 (2011), 8030–8035.
24. Kelle, S., Roes, S.D., Klein, C., et al. Prognostic value of myocardial infarct size and contractile reserve using magnetic resonance imaging. J Am Coll Cardiol 54 (2009), 1770–1777.
25. Hung, C.L., Verma, A., Uno, H., et al. Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction. J Am Coll Cardiol 56 (2010), 1812–1822.
26. Park, J.J., Park, J.B., Park, J.H., Cho, G.Y., Global longitudinal strain to predict mortality in patients with acute heart failure. J Am Coll Cardiol 71 (2018), 1947–1957.
27. Zhang, L., Jaswal, J.S., Ussher, J.R., et al. Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy. Circ Heart Fail 6 (2013), 1039–1048.
28. Sato, K., Kashiwaya, Y., Keon, C.A., et al. Insulin, ketone bodies, and mitochondrial energy transduction. FASEB J 9 (1995), 651–658.
29. Cahill, G.F. Jr., Fuel metabolism in starvation. Annu Rev Nutr 26 (2006), 1–22.
30. Kim, Y.G., Jeon, J.Y., Han, S.J., Kim, D.J., Lee, K.W., Kim, H.J., Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: a nationwide population-based cohort study. Diabetes Obes Metab 20 (2018), 1852–1858.
31. Cotter, D.G., Schugar, R.C., Crawford, P.A., Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol 304 (2013), H1060–H1076.
32. Aubert, G., Martin, O.J., Horton, J.L., et al. The failing heart relies on ketone bodies as a fuel. Circulation 133 (2016), 698–705.
33. Janardhan, A., Chen, J., Crawford, P.A., Altered systemic ketone body metabolism in advanced heart failure. Tex Heart Inst J 38 (2011), 533–538.
34. Mizuno, Y., Harada, E., Nakagawa, H., et al. The diabetic heart utilizes ketone bodies as an energy source. Metabolism 77 (2017), 65–72.
35. Uchihashi, M., Hoshino, A., Okawa, Y., et al. Cardiac-specific Bdh1 overexpression ameliorates oxidative stress and cardiac remodeling in pressure overload-induced heart failure. Circ Heart Fail, 10, 2017, e004417.
36. Schugar, R.C., Moll, A.R., Andre d'Avignon, D., Weinheimer, C.J., Kovacs, A., Crawford, P.A., Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling. Mol Metab 3 (2014), 754–769.
37. Jabs, M., Rose, A.J., Lehmann, L.H., et al. Inhibition of endothelial notch signaling impairs fatty acid transport and leads to metabolic and vascular remodeling of the adult heart. Circulation 137 (2018), 2592–2608.
38. Kappel, B.A., Lehrke, M., Schutt, K., et al. Effect of empagliflozin on the metabolic signature of patients with type 2 diabetes mellitus and cardiovascular disease. Circulation 136 (2017), 969–972.
39. Santos-Gallego, C.G., Garcia-Ropero, A., Mancini, D., et al. Rationale and design of the EMPA-TROPISM Trial (ATRU-4): Are the “cardiac benefits” of Empagliflozin independent of its hypoglycemic activity?. Cardiovasc Drugs Ther 33 (2019), 87–95.